Poorly differentiated chordomas (PDCs) represent a rare subset of notochordal neoplasms, affecting primarily children and associated with an aggressive outcome. In contrast to conventional chordomas, PDC show solid growth and increased cellularity, cytologic atypia, and mitotic activity.
| I N TR ODU C TI ON
Chordomas are relatively common, malignant bone neoplasms arising from remnants of the notochord along the craniovertebral axis, commonly involving the clivus and sacrum. 1 Chordomas make up the 4 th most frequent primary malignant bone tumor after osteosarcoma, chondrosarcoma, and Ewing sarcoma. Most chordomas occur in adults with a peak incidence in the 6 th and 7 th decades, with only a small subset, < 5%, arising in patients younger than 20 years of age. 2, 3 Pediatric chordomas show a predilection for the cranial region and may exhibit increased cellularity, solid growth, cytologic atypia, and increased mitotic activity. 4 Based on these histologic features, which are in sharp contrast with the low cellularity, physaliphorous cytology and myxoid matrix of typical chordomas, pediatric chordomas have been classified as "poorly differentiated chordoma", to also emphasize their aggressive biologic behavior and a high incidence of metastases. 4, 5 Additionally, recent studies have shown that poorly differentiated chordomas (PDCs) are associated with recurrent deletions encompassing the SMARCB1 locus, resulting in consistent loss of nuclear INI1/SMARCB1 expression and implicating this abnormality as the leading pathogenetic mechanism in these tumors. [5] [6] [7] [8] [9] [10] SMARCB1 (also known as INI1, hsnf5, or BAF47) is an ATPdependent core subunit of the switch/sucrose non-fermenting complexes. 11, 12 SMARCB1 functions as a classic tumor suppressor gene, homozygous loss of function mutations/deletions having been described initially as the hallmark of atypical teratoid/malignant rhabdoid tumors (AT/MRT) at different sites (brain, soft tissue, and kidney). 13, 14 Subsequently, loss of SMARCB1 function was identified in a variety of other tumors, such as epithelioid sarcomas, renal medullary carcinomas, myoepithelial carcinomas, epithelioid malignant peripheral nerve sheath tumors, sinonasal carcinomas, and a subset of GI tumors.
15-18
Genes Chromosomes Cancer. In this study, we sought to examine SMARCB1 abnormalities in a large series of PDCs diagnosed and managed at a single tertiary cancer institution and to establish the sensitivity of FISH method in detecting these changes as an adjunct for diagnosis.
| P A TI E NT S A ND M E TH ODS

| Clinical data
The study was approved by the Institutional Review Board of Memorial Sloan Kettering Cancer Center, New York. Cases of poorly dedifferentiated chordoma (PDC) were identified from our institutional and consultation files of the senior authors (CRA, MKR). The following clinical data were retrieved: age at diagnosis, gender, anatomic site, tumor size, history of initial metastasis before therapy, modality of therapy (surgical resection, radiotherapy, and chemotherapy), local recurrence, distant recurrence, vital status (alive or died of disease) and survival time.
| Immunohistochemistry
Immunohistochemistry (IHC) for brachyury was reviewed in all cases.
IHC for SMARCB1 was performed on 4-mm-whole sections of formalinfixed, paraffin embedded tissue blocks. The primary antibody used was a mouse monoclonal anti-BAF47 antibody (1:30; BD bioscience, San Jose, CA). Antigen retrieval, antibody incubation, and chromogen counterstaining were performed in a BenchMark ULTRA automated immunostainer (Ventana, Tucson, AZ) as previously described. Two hundred successive nuclei were examined using a Zeiss fluorescence microscope (Zeiss Axioplan, Oberkochen, Germany), controlled by Isis 5 software (Metasystems, Newton, MA). Normal copy number pattern was defined when two copies of the SMARCB1 gene were identified, with a 1:1 ratio to the control probe (i.e., telomeric-EWSR1 or 22q11). Heterozygous deletion was defined as only one copy of the gene of interest being present compared to the reference control probe on 22q (ratio 2:1). Homozygous deletion of SMARCB1 was interpreted when both copies of the gene were lost, compared to the control probes, either telomeric-EWSR1 or 22q11. A monosomy pattern (or large deletion) was defined if one allele copy of both the gene of interest and control were lost, with a ratio of 1:1. In cases where both SMARCB1 and EWSR1 signals were lost concurrently, two additional control probes were used as reference on 22q11 as previously described. 17 
| RE S U L TS
| Clinicopathologic features
A summary of the clinical characteristics is presented in Table 1 . Nine cases of poorly differentiated chordoma (PDC) were identified. One case was previously described in the study by Huang et al. 10 There were seven females and two males with ages ranging from 2 to 25 years (mean: 10), including 7 (78%) pediatric and 2 (22%) young adult patients. The anatomic sites comprised clivus (n 5 3), cervical spine (n 5 3), clivus and cervical spine (n 5 1), dura mater (n 5 1) and sacrum (n 5 1). Tumor size could be assessed in six patients, ranging from 3 to Table 2 .
| Follow-up data
Adequate therapeutic and follow-up information (Table 1) 
| D ISC USSION
Poorly differentiated chordoma (PDC) is a rare tumor frequently occurring in the pediatric age group and involving the cranial region. 5, [7] [8] [9] 19 Reported cases of PDC have been associated with aggressive biologic behavior and a high incidence of distant metastasis. 5, 8, 9 Recently, recurrent deletions at the SMARCB1 locus, resulting in loss of nuclear INI1/ SMARCB1 expression, have been described as the leading pathogenetic mechanism in PDC. 5 Based on these reports, we carried out a clinicopathologic and molecular analysis of PDCs from our institutional and consultation files, all diagnosed in the last two decades. Our main goal was to evaluate the incidence and structural abnormalities of SMARCB1 deletions in PDC and to establish if FISH methodology is the appropriate tool to investigate this genetic mechanism in the clinical setting. Second, we sought to evaluate the clinical, pathologic and survival findings in a homogeneous cohort of PDC diagnosed and managed at a single tertiary center. Similar to other reported series, our cases occurred predominately in children (7/9, 78%) and had a predilection for the cranial region (8/9, 89%). 8, 9 As previously suggested, PDCs followed an aggressive clinical course with disease progression even after multimodality therapy. 5, [7] [8] [9] In our series, 80% (4/ ease only a few months after diagnosis. In contrast to these studies, the five patients with follow-up information are still alive at a median survival of 23 months. This favorable outcome may be explained due to the fact that four of these five patients were enrolled on an on-going clinical trial using EZH2 inhibitor (Tazemetostat) after initial therapy.
Previous studies have suggested that conventional chordomas are clinically, histopathologically and molecularly distinct from PDCs. 5, 9 PDCs occur predominately in the pediatric age-group, while conventional chordomas typically affect older adults. PDCs are clinically more aggressive, with higher rates of distant metastasis and mortality.
Morphologically, PDCs lack the myxoid matrix of conventional chordomas and are characterized instead by increased cellularity, solid growth, cytologic atypia, and increased mitotic activity. Immunophenotypically, PDCs demonstrate loss of SMARCB1 expression, while conventional chordomas show nuclear retention of this marker. 5, 9 Molecularly, PDCs harbor recurrent deletions encompassing the SMARCB1 region, which are not detected in conventional chordomas. 9 PDCs should not be con- the SMARCB1 locus, resulting in loss of SMARCB1 nuclear expression.
Intragenic mutations and large deletions in the SMARCB1 locus can be detected in AT/RT. 20 In contrast to AT/RT, PDCs express brachyury, a transcription factor required for differentiation and development of the notochord during embryogenesis. 5, 9 Brachyury, a sensitive and specific marker for chordomas, is negative in AT/RT. 5, 6, 9 Epithelioid sarcoma (ES) is a rare and aggressive soft tissue neoplasm, both subtypes (proximal and distal) exhibiting SMARCB1 deletions. The study by Le Loarer et al. 17 10 clival tumor, which had been misdiagnosed as myoepithelial carcinoma due to the positive FISH result for EWSR1 gene rearrangement. On re-evaluation, complex EWSR1 regional deletions rather than a balanced rearrangement were identified, which together with positive brachyury immunoexpression supported a diagnosis of PDC with co-deletions of SMARCB1 and EWSR1. Furthermore, our previous study of SMARCB1-deleted epithelioid sarcomas showed that 25% of cases were associated with heterozygous telomeric EWSR1 deletions. 17 Similarly, co-deletions in SMARCB1 and EWSR1
genes can also occur in malignant rhabdoid tumor and myoepithelial carcinoma. The study by Hasselblatt et al. 9 showed that SMARCB1 deletions were identified in 4/7 (57%) PDC cases by FISH, but only in 2/7 (29%)
cases by multiplex ligation-dependent probe amplification (MLPA), suggesting that FISH is a more sensitive method than MLPA in the context of large homozygous deletions of PDC. In addition, the study by S api et al. 23 showed that the FISH method detected the presence of deletions in 95% of epithelioid sarcoma cases, while MLPA only in 73% of cases. These findings further confirm our prior results showing high sensitivity of FISH studies to detect homozygous deletions in epithelioid sarcomas compared to MLPA. 17 In contrast to PDC and epithelioid sarcomas in which most SMARCB1 genetic abnormalities represent large, homozygous deletions, the spectrum of alterations in rhabdoid tumors are relatively evenly distributed between whole gene deletions, intragenic deletions and duplications, nonsense mutations and frameshift mutations.
In summary, our results reveal that the dominant mechanism of SMARCB1 loss of expression in PDC is through large, homozygous deletions at the 22q11 locus which can be detected by FISH in the clinical setting. In addition, our study further documents the high likelihood of regional recurrence and distant metastasis attaching to this tumor type even after multimodality therapy.
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